Your browser doesn't support javascript.
loading
Detection of Pan drug resistance OXA-48 producing Providencia in an ICU patient for the first time in Nepal.
Sah, Ranjit; Khadka, Shusila; Shrestha, Gentle Sunder; Acharya, Subhash; Aryal, Diptesh; Shrestha, Pramesh; Kattel, Hari Prasad; Shah, Niranjan Prasad; Pokhrel, Bharat Mani; Singh, Yogendra Prasad; Rijal, Basista; Erdem, Hakan.
Afiliación
  • Sah R; Department of Microbiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.
  • Khadka S; Department of Microbiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.
  • Shrestha GS; Department of Anesthesiology (ICU), Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.
  • Acharya S; Department of Anesthesiology (ICU), Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.
  • Aryal D; Department of Anesthesiology (ICU), Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.
  • Shrestha P; Department of Anesthesiology (ICU), Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.
  • Kattel HP; Department of Microbiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.
  • Shah NP; Department of Microbiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.
  • Pokhrel BM; Department of Microbiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.
  • Singh YP; 3Research Department, Institute of Medicine, Kathmandu, Nepal.
  • Rijal B; Department of Microbiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.
  • Erdem H; IDI-IRI, Ankara, Turkey.
Article en En | MEDLINE | ID: mdl-31636898
Background: Resistance to antimicrobial agents of pathogenic bacteria has become a major problem in routine medical practices. Carbapenem resistance has long been increasing. The production of carbapenem- hydrolysing ß-lactamases (carbapenamases), which include NDM, KPC, OXA-48, IMP-1 and VIM is the most common mechanism. Case presentation: A 56 years old male presented with fever and mental changes with progressively decreasing sensorium for the last 3 days. He was admitted to Intensive care unit (ICU) with a diagnosis of meningoencephalitis. On day seven, he developed ventilator associated pneumonia due Klebsiella pnemoniae and Acinetobacter baumannii. He was on meropenem, but the isolates were susceptible to colistin, tigecyclin and amikacin solely. Hence, amikacin was started with addition of intravenous and nebulized colistin. Subsequently, vital signs improved with resolution of fever. However, on day 18, he developed fever once again with a drop in blood pressure. Inotropic support was maintained, and echinocandins and tigecycline were added to the regimen.Repeat blood and urine culture grew Providencia species, which were resistant to most of the drugs on phenotypic Kirby-Bauer disk diffusion method and are intrinsically resistant to colistin and tigecycline. Phenotypic detection of ESBL (combined disk method), MBL, KPCs, AmpC and co-producer were tested according to updated CLSI guideline and all were negative. But the Modified Hodges test was found to be positive. Consequenty, OXA-48 drug resistance pattern was brought into action by blank disc method according to A Tsakris et al., which revealed indentation of growth toward both EDTA and EDTA/PBA disk indicating production of OXA-48 carbapenamase. To confirm the resistance pattern we processed the isolated colonies for Xpert Carba-R (Cepheid) assay, which detected blaOXA-48 gene and confirmed the OXA-48 drug resistance pattern. Hence, the infecting organism was not susceptible to any of the antibiotics. The patient was kept under isolation and on 31th day of admission, he died of septic shock. Conclusions: Carbapenamase production along with intrinsic colistin resistance in infecting bacterial pathogens can cause fatal outcomes in the resource limited countries like Nepal where new antibiotic combinations ceftazidime+ Avibactam, or aztreonam +avibactam are not available. Drug resistance patterns including OXA 48 producer should be characterized in all cases by standard phenotypic methods or by Xpert Carba-R assay and larger studies are required to know the exact burden of OXA 48 producer in Nepal.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 3_ND Problema de salud: 3_neglected_diseases / 3_zoonosis Asunto principal: Choque Séptico / Beta-Lactamasas / Providencia / Farmacorresistencia Bacteriana Múltiple Tipo de estudio: Diagnostic_studies / Guideline Límite: Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Antimicrob Resist Infect Control Año: 2019 Tipo del documento: Article País de afiliación: Nepal

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 3_ND Problema de salud: 3_neglected_diseases / 3_zoonosis Asunto principal: Choque Séptico / Beta-Lactamasas / Providencia / Farmacorresistencia Bacteriana Múltiple Tipo de estudio: Diagnostic_studies / Guideline Límite: Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Antimicrob Resist Infect Control Año: 2019 Tipo del documento: Article País de afiliación: Nepal
...